A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles
- PMID: 7474102
- PMCID: PMC189602
- DOI: 10.1128/JVI.69.11.6873-6879.1995
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles
Abstract
Incorporation of Vpr into human immunodeficiency virus type 1 (HIV-1) virions is mediated by the Gag protein, independently of other viral components. We have coexpressed Vpr and Gag constructs in a vaccinia virus expression system in order to map the region of Gag involved in Vpr packaging. Deletion of the carboxyl-terminal p6 region of Gag impaired the ability of Gag to package Vpr. To confirm the role of p6 in Vpr packaging, Rous sarcoma virus (RSV)-HIV chimeras containing HIV-1 p6 were constructed. Although RSV Gag does not package Vpr into virus particles, a chimera containing HIV-1 p6 is sufficient for Vpr incorporation. To map the region of p6 involved in Vpr packaging, a series of p6 point mutations and deletion mutations was analyzed. Mutations in the N-terminal p6 proline-rich domain, for which preliminary evidence shows a marked decrease in virion incorporated RNA, did not affect Vpr incorporation. Deletion of residues 1 to 31 of HIV-1 p6 did not affect Vpr packaging, but residues 35 to 47, including an (LXX)4 domain, were required for Vpr incorporation into virus particles.
Similar articles
-
Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation.J Virol. 1995 Nov;69(11):7032-44. doi: 10.1128/JVI.69.11.7032-7044.1995. J Virol. 1995. PMID: 7474123 Free PMC article.
-
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.J Virol. 1995 Nov;69(11):6810-8. doi: 10.1128/JVI.69.11.6810-6818.1995. J Virol. 1995. PMID: 7474093 Free PMC article.
-
The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.J Virol. 1995 May;69(5):2759-64. doi: 10.1128/JVI.69.5.2759-2764.1995. J Virol. 1995. PMID: 7707498 Free PMC article.
-
Partner molecules of accessory protein Vpr of the human immunodeficiency virus type 1.DNA Cell Biol. 2004 Apr;23(4):193-205. doi: 10.1089/104454904773819789. DNA Cell Biol. 2004. PMID: 15142377 Review.
-
Vpr and Its Cellular Interaction Partners: R We There Yet?Cells. 2019 Oct 24;8(11):1310. doi: 10.3390/cells8111310. Cells. 2019. PMID: 31652959 Free PMC article. Review.
Cited by
-
HIV-1 Gag Recruits Oligomeric Vpr via Two Binding Sites in p6, but Both Mature p6 and Vpr Are Rapidly Lost upon Target Cell Entry.J Virol. 2021 Aug 10;95(17):e0055421. doi: 10.1128/JVI.00554-21. Epub 2021 Aug 10. J Virol. 2021. PMID: 34106747 Free PMC article.
-
Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging.J Virol. 2001 Sep;75(17):8348-52. doi: 10.1128/jvi.75.17.8348-8352.2001. J Virol. 2001. PMID: 11483780 Free PMC article.
-
A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm).J Virol. 1999 Dec;73(12):9992-9. doi: 10.1128/JVI.73.12.9992-9999.1999. J Virol. 1999. PMID: 10559313 Free PMC article.
-
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.J Virol. 2000 May;74(10):4621-33. doi: 10.1128/jvi.74.10.4621-4633.2000. J Virol. 2000. PMID: 10775598 Free PMC article.
-
Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.J Virol. 1998 Jul;72(7):5441-8. doi: 10.1128/JVI.72.7.5441-5448.1998. J Virol. 1998. PMID: 9620999 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials